What to Expect After a Prostate Cancer Diagnosis

Hearing the words “you have prostate cancer” is a life-altering moment for any man. In an instant, conversations in the examination room seem to blur, and the mind immediately leaps to worst-case scenarios: invasive surgery, loss of urinary control, permanent erectile dysfunction, or concerns about survival.

Renowned robotic urologic oncologist Dr. David Samadi—Director of Men’s Health at St. Francis Hospital and pioneer of the SMART (Samadi Modified Advanced Robotic Technique) prostatectomy—stresses a vital first principle to newly diagnosed patients: a prostate cancer diagnosis is rarely an overnight medical emergency.

Because prostate tumors typically grow slowly, men have the time to pause, gather complete diagnostic data, obtain a second opinion, and evaluate their treatment options carefully. Understanding what to expect during the initial weeks and months after diagnosis transforms fear into clinical clarity and empowers patients to take charge of their health.

Phase 1: Decoding Your Pathology and Risk Level

Before choosing any therapy, you must look beyond the general term “cancer”. Prostate cancer encompasses a broad spectrum of disease, ranging from indolent, low-grade micro-foci to aggressive, high-risk malignancies. Dr. Samadi reviews four core diagnostic benchmarks to establish an accurate biological roadmap:

• PSA Kinetics and Velocity: Total Prostate-Specific Antigen (PSA) provides a baseline, but the rate of rise (velocity) and doubling time (PSADT) over months provide insights into how quickly tumor cells may be multiplying.
• The Gleason Score and Grade Group: Pathologists examine biopsy cores to evaluate cellular architecture on a scale from Grade Group 1 (Gleason 3+3=6, least aggressive) to Grade Group 5 (Gleason 9–10, highly aggressive). This score directly indicates tumor biology and risk of progression.
• Core Distribution and Tumor Volume: Knowing how many biopsy cores tested positive, along with the percentage of tumor tissue within each core, reveals whether cancer is focal or widespread within the gland.
• 3-Tesla Multiparametric MRI (mpMRI): High-resolution imaging determines whether the tumor is organ-confined or abuts the outer prostatic capsule, neurovascular bundles, or seminal vesicles.

[DIAGNOSTIC RISK STRATIFICATION]

│

┌───────────────────────┼───────────────────────┐

▼ ▼ ▼

[LOW RISK] [INTERMEDIATE] [HIGH RISK]

• Grade Group 1 (3+3) • Grade Group 2/3 (3+4, 4+3) • Grade Group 4/5 (8-10)
• PSA < 10 ng/mL • PSA 10–20 ng/mL • PSA > 20 ng/mL
• T1c to T2a • T2b to T2c • T3 (Capsular Extension)

Phase 2: Evaluating Your Treatment Options

Dr. Samadi strongly emphasizes that modern prostate cancer care does not follow a “one-size-fits-all” model. Depending on your risk profile, age, overall health, and personal priorities, management falls into three main categories:

1. Active Surveillance

• Who It’s For: Men with low-risk, indolent disease (Gleason 6 / Grade Group 1, low tumor volume, low PSA density).
• What to Expect: Rather than rushing into treatment, the cancer is closely monitored through serial PSA testing every 3 to 6 months, periodic mpMRI imaging, and confirmatory surveillance biopsies. Definite curative intervention is held in reserve until the tumor shows measurable signs of progression.

2. Robotic Radical Prostatectomy (SMART Technique)

• Who It’s For: Men with localized intermediate- or high-risk cancer, or younger, healthy patients who desire definitive physical removal of the tumor.
• What to Expect: Complete surgical removal of the prostate gland, seminal vesicles, and selective pelvic lymph nodes. Dr. Samadi utilizes his custom SMART technique, which avoids cautery heat near the delicate erectile nerves and incorporates maximum urethral length preservation to optimize early return of urinary continence and sexual function. Surgery provides an accurate final pathological stage and a target PSA of zero (<0.05–0.1ng/mL).

3. Radiation Therapy (EBRT / Brachytherapy)

• Who It’s For: Patients who are not surgical candidates due to severe cardiovascular or pulmonary comorbidities, or those who prefer non-invasive options.
• What to Expect: External beam radiation (often paired with temporary androgen deprivation therapy/hormone therapy) or radioactive seed implants. While effective at treating cancer cells, radiation leaves the treated prostate in place, resulting in a gradual drop in PSA over 12 to 18 months rather than an immediate drop to zero.

Phase 3: The Surgical Recovery Pathway

For patients who choose robotic surgery, knowing what lies ahead physically and practically removes uncertainty:

Phase 4: Emotional Health and Survivorship

Prostate cancer affects more than physical anatomy—it impacts a man’s mental well-being, intimacy, and sense of identity. Dr. Samadi emphasizes that open, proactive communication is central to long-term recovery:

• Include Your Partner: Treatment choices directly impact both partners. Attending appointments together fosters shared decision-making and reduces emotional stress.
• Adopt Prostate-Healthy Nutrition: Adopt a Mediterranean-style dietary pattern rich in cruciferous vegetables, lycopene-rich cooked tomatoes, and wild fish, while limiting processed meats and refined sugars.
• Stay Physically Active: Routine cardiovascular exercise and resistance training enhance energy levels, support cardiovascular health, and speed pelvic recovery.

Frequently Asked Questions (FAQ)

How quickly do I need to make a decision after diagnosis?

Prostate cancer is typically slow-growing, which means you have time to thoroughly review your biopsy report, consult with specialists, and obtain a second opinion. Taking 2 to 4 weeks to review your pathology, explore treatment modalities, and choose the right surgical team will not compromise your oncologic cure.

Why is surgeon case volume so critical in prostate cancer?

The prostate is closely surrounded by the delicate neurovascular bundles responsible for erections and the external urinary sphincter responsible for continence. A surgeon who has performed thousands of robotic procedures has refined the tactile nuances and visual recognition needed to excise the tumor cleanly while preserving microscopic nerve fibers.

What should my PSA level be after surgery?

Following a radical prostatectomy, all prostate tissue is removed. Because PSA is produced almost exclusively by prostate cells, your PSA level should drop to an undetectable baseline (<0.05to<0.1ng/mL) within 6 to 8 weeks and remain undetectable during routine surveillance.

Conclusion

A prostate cancer diagnosis brings legitimate concerns, but it is also one of the most treatable malignancies in modern medicine. By avoiding rushed decisions, understanding the specifics of your biopsy pathology, and partnering with an experienced urologic oncologist, you can pursue a personalized treatment plan focused on two non-negotiable goals: curing the cancer and preserving your long-term quality of life.

Consult with Dr. David Samadi

Navigating a new prostate cancer diagnosis requires specialized, high-volume surgical expertise. Dr. David Samadi is a board-certified urologist, Director of Men's Health at St. Francis Hospital, and pioneer of the SMART robotic technique with more than 10,000 successful surgeries performed.

• Office Locations: 485 Madison Avenue, 21st Floor, New York, NY 10022 & Roslyn, NY
• Clinical Specialization: Robotic Radical Prostatectomy, Prostate Cancer Diagnosis, Second Opinions, and Survivorship Care
• Direct Consultation Line: (212) 365-5000
• Case Review Portal:roboticoncology.com